These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12799622)

  • 1. Oral melphalan as a treatment for platinum-resistant ovarian cancer.
    Hasan J; Jayson GC
    Br J Cancer; 2003 Jun; 88(12):1828-30. PubMed ID: 12799622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer.
    Davis-Perry S; Hernandez E; Houck KL; Shank R
    Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
    Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
    Mougenot P; Fabbro M; Bressolle F; Pouessel D; Culine S; Pinguet F
    Oncol Rep; 2006 Jan; 15(1):237-41. PubMed ID: 16328062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of recurrent ovarian carcinoma: current status and future directions.
    Martin LP; Schilder RJ
    Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.
    Satthapong D; Tangjitgamol S; Manusirivithaya S; Pataradool K
    J Med Assoc Thai; 2007 Mar; 90(3):411-9. PubMed ID: 17427513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
    Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
    J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.
    Colombo N; Gore M
    Crit Rev Oncol Hematol; 2007 Nov; 64(2):129-38. PubMed ID: 17566758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.